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1. Introduction
  Coronary heart disease (CHD) is one of the primary 
diseases leading to death worldwide. CHD is due to coronary 
atherosclerosis (AS) stenosis or occlusion that leads to 
myocardial ischemia hypoxia. Coronary artery disease 
(CAD) not only includes lipid accumulation within the artery 
wall; it also involves inflammatory reactions and other 
immune processes in the occurrence and development of 
AS. Recent studies have found that in addition to regulating 
glucose and lipid metabolism, some adipocytokines, such 
as omentin and visfatin, also play an important role in 
regulating immune response and inflammation[1].
  In 2003, Yang et al[2] suggested omentin as a new 
adipocytokine secreted from the omental adipose tissue. 
Omentin was demonstrated to enhance insulin-mediated 
Objective: To investigate the alteration of plasma levels of omentin-1 and visfatin in elderly 
patients with coronary heart disease (CHD) and heart failure. Methods: Plasma omentin-1 and 
visfatin levels were measured in 90 subjects (29 stable angina pectoris (SAP) cases, 30 unstable 
angina pectoris (UAP) cases and 31 age- and sex-matched healthy controls (age 曒 60 years) by 
enzyme-linked immunosorbent assay methods. According to the New York Heart Association 
classification, 59 CHDs were divided into three groups: functional I class, 11 cases; functional 栻
/栿 class, 36 cases; and functional IV class, 12 cases. Results: The plasma level of omentin-1 
in CHD patients was significantly lower than that of the control group. Omentin-1in SAP group 
and UAP group were significantly lower compared to the control group (there was no statistical 
significance between UAP group and SAP group; P>0.05). The plasma level of visfatin in CHD 
patients was significantly higher than that of the control group. Similarly, visfatin in SAP group 
and UAP group were all significantly higher compared to the control group, while there was no 
statistical significance between UAP group, and SAP group. The plasma omentin-1 level was 
negatively correlated with SBP (r=-0.264, P<0.05), positively correlated with HDL-c level (r=0.271, 
P<0.05); the plasma visfatin level was positively correlated with TC (r=0.292, P<0.05), negatively 
correlated with HDL-c level (r=-0.266, P<0.05). There was a negative correlation between 
plasma omentin-1 and visfatin levels (r=-0.280, P<0.05). Moreover, multiple linear stepwise 
regression analysis showed that omentin-1 and visfatin levels might be affected by HDL-c level. 
Logistic regression analysis showed that visfatin could be an independent risk factor of CHD. 
Conclusions: Decreased levels of omentin-1 and increased levels of visfatin may be involved 
in the occurrence and development of CHD. Omentin-1 and visfatin, independently, may be 
protective and pro-inflammatory cytokines. Additionally, both omentin-1 and visfatin may be 
related to lipid metabolism. Visfatin may be an independent risk factor of CHD. 
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glucose-uptake in adipocytes, activate proteinkinase 
Akt/PKB, and improve the insulin sensitivity of fat cells. 
Yamawaki et al[3] demonstrated for the first time that 
omentin plays an anti-inflammatory role by preventing the 
TNF-毩-induced COX-2 expression in vascular endothelial 
cells. Kazama et al[4] found that omentin inhibits TNF-毩
-induced inflammation of invascular smooth muscle cells 
(SMCs), and its anti-inflammatory role is attributed, at least 
in part, to the inhibition of superoxide production. Omentin 
has two isoforms: omentin-1 and omentin-2; omentin-1 
was shown to be the major circulating isoform in human 
plasma[3]. In addition, omentin-1 was also regarded as a 
protective cytokine in the metabolic imbalance condition 
of the body[5]. Previous research found that the plasma 
levels of omentin were decreased in patients with CHD, 
which indicated that omentin-1 may also be involved in 
the occurrence of coronary AS. However, research in the 
involvement of omentin in the development of heart failure 
patients with CHD is limited.
  In 2005, Fukuhara et al[6] discovered visfatin-another 
adipocytokine mainly secreted from visceral adipose 
tissue that has+ insulin-mimetic effects and roles in 
glucose and lipid metabolism regulation. The inflammatory 
response, immune regulation, and other biological activity 
are closely associated with obesity, type 2 diabetes 
and insulin resistance. Sonoli et al[7] found that visfatin 
had antiapoptotic activity and had a regulatory role in 
inflammation. Plasma levels of visfatin increased with 
the increase of C-reactive protein (CRP) levels, further 
suggesting visfatin’s inflammatory effects[8]. Relevant 
research indicated that these inflammatory effects increased 
the risk of cardiovascular events in patients with obesity. 
Malyszko et al[9] reported that visfatin is also related to hs-
CRP. Moreover, several studies have found that visfatin 
can up-regulate the expression of inflammatory cytokines 
(such as IL-6, IL-8, MCP-1), and consequently, these 
inflammatory cytokines can increase the expression of 
visfatin, thus accelerating the development of cardiovascular 
disease. Taken together, these research results suggest 
that there may be a close link between inflammation and 
adipokines. Other studies, however, found that visfatin 
had no correlation with hs-CRP; thus, visfatin may be 
unrelated to the pro-inflammatory effect. Although there 
are arguments about whether visfatin is a pro-inflammatory 
cytokine or an anti-inflammatory factor, recent studies 
lean towards the claim that visfatin is a novel inflammatory 
regulator with pro-inflammatory effects. Lastly, research 
suggests that visfatin also plays an important role in the 
process of unstable atherosclerotic plaque[10]; however, the 
mechanism of visfatin in cardiovascular diseases is still not 
clear. Therefore, our study’s aim is to observe the changes 
of plasma omentin-1 and visfatin levels, and discuss their 
effects in the occurrence of CHD within a group of elderly 
CHD patients.
2. Materials and methods
2.1. Research objects
   All patients were selected at the Second Xiangya Hospital 
of Central South University from July 2012 to December 2012 
by coronary angiography or coronary CT angiography. Fifty-
nine elderly patients diagnosed with CHD were chosen and 
31 healthy subjects served as a control group. All subjects 
were aged over 60 years. Based on clinical symptoms, the 
CHD group was divided into two groups: a stable angina 
pectoris (SAP) group and an unstable angina pectoris (UAP) 
group. With regards to the CHD grading of New York Heart 
Association (NYHA) classification method, the CHD group 
was divided into three groups based on the conscious 
activity found within patients, namely functional 栺 class, 
11 cases; functional 栻/栿, class 36 cases; and functional 桇, 
class 12 cases. All subjects signed informed consent.
2.2.  Diagnostic criteria
  Stable angina pectoris is due to typical angina pectoris 
attack caused by myocardial ischemia and hypoxia. Its 
clinical manifestation is relatively stable within 1 to 3 
months, with same pain-onset time daily and weekly, with 
equal emotional and labor pain evoked, and with no changes 
in nature/ range/ duration in each attack. Relief time of pain 
is also similar with nitroglycerin. 
  Unstable angina pectoris is a formerly stable angina 
pectoris. Within one month, the pain increased seizure 
frequency, severity, and duration. Factors, such as nitrates, 
with alleviating effect are reduced. Moreover, new angina 
pectoris occur within one month and pain occurs due to 
lighter load; it can occur while at rest or can be induced by 
slight activity. 
  Heart function classification: according to the NYHA 
classification method proposed in 1928, the degree of 
activity induced heart failure symptoms and heart function 
was divided into four levels.
  Diagnostic criteria of the elderly: in accordance with the 
elderly branch of standard Chinese Medical Association in 
1990, subjects should be 60 years of age or older.
2.3. Exclusion criteria
  Subjects with the following were excluded: severe liver/ 
kidney dysfunction; severe systemic disease (such as the 
diseases of respiratory system/ digestive system/ nervous 
system etc.); malignant tumor; acute/ chronic infectious 
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diseases; autoimmune disease or connective tissue disease; 
and a major trauma or surgical operation over the past three 
months.
2.4. Apparatus and reagents
  The following apparatus were used: 80-2 desktop 
centrifuge, produced by the Shanghai Operation Machinery 
Factory; ELX800 automatic enzyme-mark analyzer, 
manufactured by Bio-EK Instrument Inc; Omentin ELISA 
kit and visfatin ELISA kit, provided by Wellbiotechnology 
Company, Changsha.
2.5. Research methods
2.5.1. Sample processing
  All subjects admitted to the hospital fasted for 10 h. Height, 
weight, and blood pressure were measured. Subsequently, 
venous blood was drawn the following morning for routine 
blood test, liver and kidney function test, C reactive protein 
test and so on (Department of laboratory quality control 
index by special inspection). At the same time, 3 mL elbow 
venous blood was transferred into EDTA anticoagulant 
tubes, shaken, and centrifuged at 2 000 r/min 20 min. The 
supernatant was then stored at -80 曟, to be used for the 
determination of plasma concentration of omentin -1 and 
visfatin.
2.5.2. Determination of plasma Omentin-1  
  Plasma concentrations of omentin-1 were determined 
using an enzyme-linked immunosorbent assay (ELISA) kit 
(Wellbiotechnology Company, Chang sha) with detection 
range of 50 ng/L to 1 000 ng/L. 
2.5.3. Determination of plasma visfatin    
  Plasma concentrations of visfatin were determined using 
an ELISA kit (Wellbiotechnology Company, Changsha) wih 
detection range of 1 毺g/L to 20 毺g/L.
2.6. Statistical analysis
  The data were analyzed using the statistical package 
SPSS 17.0. Measurement data were expressed as mean暲
SEM. Normality and homogeneity of variance test were used 
for each group. Differences were evaluated by two-tailed 
Student’s t test or ANOVA. Pearson analysis method was 
used for correlation analysis. Multiple factors were analyzed 
by multiple linear stepwise regression analysis. Logistic 
regression analysis was applied to evaluate the correlation 
between the independent variables and CHD. Statistical 
significance was set at P<0.05.
 3. Results
3.1. General information
  The clinical and biochemical characteristics of the study 
subjects are provided in Table 1. Compared with the control 
group, the CHD group’sBody Mass Index (BMI) and serum 
levels of TC, TG, and CRP increased significantly, while 
serum levels of HDL-c decreased significantly. There was 
a significant statistical difference between the two groups 
(P<0.05), but there were no significant changes in age, blood 
pressure, LDL-c, ALT, AST, BUN, and Cr between the two 
groups (P>0.05).
Table 1
Characteristics of study subjects in CHD and Control group.   
Indexes Control group (n=31) CHD group (n=59) P value
Sex(male/femele)         20/11         36/23
Age (years)   75.85暲8.99   73.90暲8.39 0.321
BMI (Kg/m2)   22.32暲2.61   24.05暲2.92 0.007
SBP (mmHg) 132.84暲12.55 134.83暲14.31 0.515
DBP (mmHg)   75.81暲7.92   74.81暲10.31 0.641
TC (mmol/L)     4.20暲0.57     4.72暲0.86 0.004
TG (mmol/L)     1.20暲0.48     1.55暲0.62 0.006
LDL-C (mmol/L)     2.72暲0.78     2.85暲1.03 0.542
HDL-C (mmol/L)     1.20暲0.22     1.03暲0.23 0.001
ALT (毺/L)   15.82暲6.19   20.74暲14.96 0.080
AST (毺/L)   20.92暲4.94   22.76暲8.81 0.283
BUN (mmol/L)     6.10暲1.99     6.16暲2.24 0.899
Cr (mmol/L)   79.33暲30.40   87.58暲23.69 0.159
CRP (mg/L)     3.66暲1.02     7.51暲2.30 0.003
3.2. Analysis of plasma levels of omentin-1 and visfatin 
between the CHD and control group
3.2.1. Analysis of plasma levels of omentin-1 between CHD 
and control group
  Using the t test for independent samples, there was a 
significant decrease in omentin-1 observed in the CHD 
group compared to the Control group [(717.63暲229.11) ng/L, 
(1 115.49暲361.41) ng/L, P=0.000]. 
3.2.2. Analysis of plasma levels of visfatin between CHD and 
control group
  Using the t test for independent samples, there was a 
significant increase in visfatin level observed in the CHD 
group compared to the Control group [(19.22暲6.73 毺g/L, 
(13.31暲1.69) 毺g/L, P=0.002). 
3.3. Analysis of plasma levels of omentin-1 and visfatin in 
SAP, UAP and Control group
3.3.1. Analysis of plasma levels of omentin-1 in SAP, UAP 
and control group
  Using one-way ANOVA test, a significant decrease in 
omentin-1 was observed in SAP and UAP groups, in contrast 
with the control group [(780.32暲273.19) ng/L, (1 115.49暲
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361.41) ng/L, P=0.003; (652.81暲152.94) ng/L, (1 115.49暲
361.41) ng/L, P=0.000]. The plasma levels of omentin-1 in 
the UAP group were lower than that in the SAP group, but 
the difference had no statistical significance [(652.81暲
152.94) ng/L, (780.32暲273.17) ng/L, P>0.05].
3.3.2. Analysis of plasma levels of visfatin in SAP, UAP and 
control group
  Using one-way ANOVA test, a significant increase in 
visfatin was observed in SAP and UAP groups, in contrast 
with the Control group [(17.92暲4.19) 毺g/L, (13.31暲1.69) 毺g/
L, P=0.002; (20.43暲8.31) 毺g/L, (13.31暲1.69) 毺g/L, P=0.000]. 
The plasma levels of visfatin in the UAP group were higher 
compared with the SAP group; however, the difference had 
no statistical significance [(20.43暲8.31) 毺g/L, (17.92暲4.19) 
毺g/L, P>0.05].
3.4. Analysis of plasma levels of omentin-1 and visfatin in 
different NYHA classifications of the CHD group
3.4.1. Analysis of plasma levels of omentin-1 in different 
NYHA classifications of the CHD group
  There were significant increases in omentin-1 levels in 
(NYHA) functional栺class group than in functional 栻/栿
class group, functional 桇 class group [(1 033.87暲277.84) ng/
L, (676.58暲137.25) ng/L, (540.35暲59.49) ng/L, all P<0.05]. The 
plasma levels of omentin-1 in functional 桇 class group were 
significantly decreased compared to that of functional 栻/栿 
class group, and the difference had statistical significance 
[(540.35暲59.49) ng/L, (676.58暲137.25) ng/L, P=0.000].
3.4.2. Analysis of plasma levels of visfatin in different NYHA 
classifications of the CHD group
  There were significant increases in visfatin levels in 
(NYHA) functional 桇 class group than in functional 
栻/栿 class  group and funct ional  栺 class  group 
[(25.23暲11.30 毺g/L, (19.08暲2.97) 毺g/L, (13.00暲1.19) 毺g/
L, all P<0.05). The plasma levels of visfatin in functional 栻
/栿 class group were significantly increased compared to 
that of the functional 栺 class group. The difference had 
statistical significance [(19.08暲2.97) 毺g/L, (13.00暲1.19) 毺g/
L, P=0.002].
3.5. Correlations
  A significant correlation between lower omentin-1 levels 
and higher Systolic Pressure (SBP) (r=-0.264, P<0.05), and 
lower HDL-c levels (r=0.271, P<0.05) was observed. We also 
observed a significant correlation between higher visfatin 
levels and higher TC levels (r=0.292, P<0.05), and lower 
HDL-c levels (r=-0.266, P<0.05). Lastly, there was also a 
significant correlation between lower omentin-1 levels and 
higher visfatin levels (r=-0.280, P=0.032) (Figure 1).
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Figure 1. Correlation between omentin-1 and visfatin levels. 
3.6. Multiple linear stepwise regression analysis of the factors 
that influence omentin-1 and visfatin levels
  The results of multiple linear stepwise regression analysis 
demonstrated that plasma levels of omentin-1 was affected 
by HDL-c levels (P=0.006), and the regression equation 
was Y=240.100+563.067XHDL-c; plasma levels of visfatin was 
affected by HDL-c levels (P=0.025), and the regression 
equation was Y=25.529-7.720XHDL-c.
3.7. Logistic regression analysis
  As shown in Table 2, logistic regression analysis 
demonstrated that the risk of CHD was significantly 
associated with HDL-c (P=0.006), CRP (P=0.000), and visfatin 
levels (P=0.001).
Table 2
Logistic regression analysis.
Factors OR     95%CI           P-values
HDL-c                                  0.007 0.000-0.194 0.003
CRP                                  2.030 1.387-2.972 0.000
Visfatin                               1.948 1.302-2.914 0.001
4. Discussion
4.1. Relations between CHD and omentin-1 levels
  The adipokine theory is a widely accepted theory. 
It suggests that adipocytokines are involved in the 
inflammatory response, which directly promotes the 
occurrence of CHD. Omentin-1 was reported to be expressed 
specifically in omental adipose tissue. Omentin-1 was a new 
anti-inflammatory cytokine and its anti-inflammatory role 
was attributed, at least in part, to the inhibition of superoxide 
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production[3,4]. Omentin mRNA was predominantly found in 
epicardial and omental adipose tissues[11].
  Previous studies[12,13] have demonstrated that omentin 
levels were lower in patients with CAD compared with 
controls. Moreover, serum omentin-1 concentrations were 
independently correlated with CAD. Patients with ACS also 
had lower serum concentrations of omentin-1 compared with 
patients with SAP[13]. However, other research[12] suggested 
that there were no changes in plasma omentin levels in ACS 
group compared with SAP group. We reported that plasma 
levels of omentin-1 were significantly lower in patients 
with CHD compared with controls. Furthermore, there was 
a decreasing trend in omentin-1 levels in UAP group than 
SAP group, but the difference had no statistical significance. 
This result was in accord with the result of previous studies. 
Consequently, lower omentin-1 levels may be related to the 
occurrence of CHD.
  Further analysis showed that there was a positive 
correlation between plasma concentrations of omentin-1 and 
HDL-c levels. Omentin may be involved in the development 
process of lipid metabolism and AS through the regulation of 
the phosphorylation of Akt. Initially, omentin may improve 
insulin sensitivity by increasing the phosphorylation of 
Akt[14]. Decreased omentin levels have been related with 
the insulin resistance (IR)[3]. Moreover, hyperinsulinemia 
induced by IR not only can promote the synthesis of TC in 
the liver; it can reduce the fat protease activity causing TG 
decomposition barrier. The elevated levels of TG can hinder 
the conversion of very low-density lipoprotein (VLDL) into 
HDL; therefore, VLDL levels increase and HDL-c decrease. 
Clinical and epidemiological studies have proved that 
there is a negative correlation between HDL-c levels and 
CHD incidence rate. Studies[3] also found that there was a 
negative correlation between omentin-1 levels and HDL-c 
levels. Moreover, Cai et al[15] found that HDL-c levels were 
independently correlated with omentin-1 concentrations. 
Thus, these studies support our results. We speculated that 
omentin -1 may be a protective factor for CHD. However, the 
use of lower levels of omentin-1 as an evaluated indicator of 
risk factors in patients with CHD must be further evaluated, 
and more clinical studies are needed to confirm these 
findings.
  In addition, Duan et al[16] demonstrated for the first time 
that omentin can inhibit osteoblastic differentiation of 
calcifying vascular smooth muscle cells (CVSMCs) via PI3K/
Akt signaling pathway. This suggests that the lower omentin 
levels in obese (specially visceral obese) subjects contribute 
to the development of arterial calcification, and that omentin 
plays a protective role against arterial calcification. Xie et 
al[17] found that omentin-1 ameliorates arterial calcification 
and bone loss in vivo through the regulation of the RANK 
signaling pathway. Artery calcification usually occurs on 
the basis of arteriosclerosis. Elastic fiber degeneration and 
AS lead to the decline in aortic elasticity, and once the 
vessel accumulates with arterial calcification, the degree 
of hardening becomes relatively more serious. With the 
increase of age, large artery elasticity decreases gradually, 
and SBP increases while DBP decreases, which lead to 
the increase in pulse pressure. If combined with arteriolar 
sclerosis, SBP, and DBP increase. Our results indicate that 
plasma omentin-1 levels were negatively associated with 
SBP, which suggests that SBP was higher, omentin-1 level 
was lower, and the degree of arteriosclerosis may be more 
substantial. Shibata et al[18] studied a group of male patients 
with CHD; their results supported the findings of our study. 
However, to date, there are different opinions regarding 
coronary artery calcification (CAC). Some studies suggested 
that CAC was a “bad” phenomenon; others believed that 
artery calcification could be a protective effect. Thus, it 
should be elucidated whether omentin has a "beneficial" 
effect in the development of AS. In addition, there has been 
little research on the relationship between omentin-1 levels 
and blood pressure, which also need further study.
  El et al[19] reported that TNF-毩 played a significant role 
in the pathophysiology of congestive heart failure (CHF). 
Omentin played an anti-inflammatory role by preventing the 
TNF-毩-induced superoxide or vascular inflammation[20]. 
Zhong et al[21] found that omentin may inhibit TNF-毩
-induced expression of adhesion molecules in endothelial 
cells by blocking the ERK/NF-kappaB pathway. In 
our study, patients in a higher NYHA class show lower 
concentrations of omentin-1 than those in a lower NYHA 
class, which suggest that decreased omentin-1 levels may 
be associated with the severity of heart failure. Based on 
these studies, omentin-1 could play an important role in 
the development of CHD; however, its mechanism is still 
unclear. We speculate that omentin-1 may inhibit TNF-毩
-induced expression of vascular cell adhesion molecule-1 
(VCAM-1) by blocking the ERK/NF-kappaB pathway to 
protect CHD patients with heart failure, but this should be 
studied further.
4.2. Relations between CHD and visfatin levels
  Visfatin is another kind of adipocytokine discovered in 
recent years, which may be associated with obesity, blood 
glucose metabolism and cardiovascular risk factors. Visfatin 
proteins were found to be predominantly released by visceral 
white adipose tissue (WAT) macrophages, and visfatin was 
considered to be a pro-inflammatory marker[22]. Visfatin is a 
pro-inflammatory factor, which can increase the expression 
of TNF-毩, interleukin-8 (IL-8), interleukin-6 (IL-6) and 
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other cytokines, thereby accelerating the development of 
cardiovascular disease[23]. Ooi et al[24] reported that visfatin 
and its genetic variants were associated with adiposity, 
obesity-related morbidities and adverse cardiometabolic 
parameters, which suggest that visfatin played a significant 
role in the development of obesity-related morbidities 
and cardiometabolic risk. Dahl et al[10] found that visfatin 
may be an inflammatory mediator, localized in foam cell 
macrophages within unstable atherosclerotic lesions, 
which may potentially play a role in plaque destabilization. 
Previous studies have found that visfatin has a role similar 
with nicotinamide phosphoribosyltransferase (Nampt), and 
was formerly known extracellularly as pre-B cell colony-
enhancing factor (PBEF), and intracellularly as Nampt. 
Pillai et al[25] found that cardiomyocytes were  capable of 
secreting Nampt during stress, and exogenous Nampt was 
a positive regulator of cardiac hypertrophy and adverse 
ventricular remodeling. In addition, visfatin exerts direct 
cardioprotective effects[26]. Visfatin mRNA expression 
could be up-regulated in the fat tissue of obesity due to 
hypoxia[27], which suggest that myocardial ischemia may 
have up-regulated the expression of visfatin. Hence, present 
studies are inclined to accept that visfatin levels accelerate 
the occurrence and development of cardiovascular diseases 
amidst different opinions about whether visfatin is a 
protective factor or a pro-inflammatory cytokine in the 
development of cardiovascular diseases. Plasma visfatin 
concentrations were increased in participants diagnosed 
with cardiovascular diseases[28]. Plasma levles of visfatin in 
patients with CHD were also found to increase significantly 
compared to that of the control group, and the plasma 
levels of visfatin in UAP group had an increasing tendency 
compared with SAP group, but there was no significant 
difference. Our results suggest that visfatin may be 
expressed abnormally in patients with CHD, and visfatin 
may be involved in the occurrence of CHD. However, there 
seems to be no relationship with the urgent or delayed onset 
of CHD, which needs to be further studied.
  Visfatin was also shown to have insulin-mimetic 
effects in cultured cells and lowered plasma glucose 
levels in mice[6]. Yan et al[29] found that visfatin could 
increase insulin sensitivity by up-regulating the levels of 
peroxisomal proliferator-activated receptor 毭 (PPAR毭
) mRNA and insulin receptor substrate-1 (IRS-1) tyrosine 
phosphorylation, and thus regulated lipid metabolism. 
Visfatin may regulate cholesterol metabolism in mice 
by promoting the expression of sterol regulatory element 
binding protein 2 (SREBP2) and HMG CoA reductase, thus, 
decrease the cholesterol (including HDL-c) levels[30]. In 
addition, visfatin perhaps affected TG metabolism through 
the alteration of one or several genes of dominanting TG 
metabolism upstream, and also can regulate the metabolism 
of cholesterol[31]. Moreover, Sethi et al[32] found that visfatin 
can convert plasma glucose into TG, and promote the 
accumulation of TG in preadipocytes. Mu et al[33] found 
that visfatin levels were strongly correlated with serum TG 
levels and LDL-c levels, and negatively correlated with 
HDL-c levels. In our study, we observed that TC levels 
and TG levels in CHD group were significantly higher than 
that of control group and HDL-c levels were significantly 
lower than that of control group. Moreover, v isfatin levels 
were strongly positively correlated with serum TC levels, 
and negatively correlated with HDL-c levels. The result of 
multiple linear stepwise regression analysis suggested that 
visfatin levels may be affected by HDL-c levels, and logistic 
regression analysis showed that visfatin was an independent 
risk factor of CHD. The abovementioned results suggested 
that visfatin could be involved in lipid metabolism, which 
leads to the occurrence of CHD. However, these results had 
differences with other current research, so further study and 
verification is needed.
  Furthermore, Kim et al[34] found that visfatin induced 
the activation of signal transducer and activator of 
transcription 3 (STAT3), as characterized by increased 
tyrosine phosphorylation, nuclear translocation, and DNA-
binding activity in human endothelial cells.  Visfatin 
also significantly up-regulated mRNA and protein levels 
of endothelial interleukin-6 (IL-6). In vitro, Liu et al[35] 
demonstrated that visfatin could up-regulate the secretion 
of MCP-1 and IL-6 in a dose- and time-dependent manner 
in human umbilical vein endothelial cells. In addition, 
visfatin-induced MCP-1 and IL-6 production involved p38 
MAPK, PI3K, and ERK 1/2 pathways in human umbilical 
vein endothelial cells as determined by inhibition with 
specific inhibitors. Another research[36] also found that the 
levels of serum IL-6 and TNF-毩 in patients with CHF were 
significantly increased in comparison with control group, 
and there were significant differences of serum IL-6 and 
TNF-毩 levels among NYHA 栻, 栿 and 桇 in patients with 
congestive heart failure (CHF), which suggested that serum 
IL-6 and TNF-毩 level might play an important role in 
pathogenesis of CHF. Thus, we presume that visfatin might 
up-regulate IL-6 levels by inducing the activation of STAT3, 
as characterized by increased tyrosine phosphorylation, to 
participate in the development of CHF. Morever, Kim et al[37] 
found that visfatin was a vascular inflammatory molecule 
that increases the expression of the inflammatory CAMs, 
ICAM-1 and VCAM-1, through ROS-dependent NF-毷
B activation in endothelial cells. Thus, we speculate that 
visfatin up-regulates VCAM-1 levels through activating 
ROS-dependent NF-毷B, and then participates in the 
development of CHF. Our study found that visfatin levels 
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gradually increased with the increase of NYHA grade in 
patients with CHF, and there were significant differences 
among NYHA栺 class, NYHA 栺栻/栿 class, NYHA 桇 class 
groups, demonstrating that visfatin might participate the 
development of CHF, and that the plasma levels of visfatin 
could reflect the severity of heart function. However, further 
investigation about this mechanism is needed.
4.3. Relevance between omentin-1 and visfatin levels 
  Yamawaki et al[20] demonstrated that omentin played an 
anti-inflammatory role by preventing the TNF-毩-induced 
superoxide or vascular inflammation. In addition, omentin 
may inhibit TNF-毩-induced expression of adhesion 
molecules in endothelial cells by blocking the ERK/NF-
kappaB pathway[21]. Morever, visfatin can up-regulate the 
expression of inflammatory cytokines (such as IL-6, IL-8, 
MCP-1 and so on). Also, visfatin was a vascular inflammatory 
molecule that increases the expression of the inflammatory 
CAMs, ICAM-1 and VCAM-1, through ROS-dependent 
NF-毷B activation in endothelial cells[37]. Taken together, 
we speculate that omentin-1 and visfatin regulate the 
expression of VCAM-1 and IL -6 through different pathways, 
and then become involved in the development of CHF. Our 
study found that omentin-1 levels were strongly correlated 
with visfatin levels in senile CHF, which suggested that 
omentin-1 and visfatin both played an important role in the 
development of senile CHF. However, the two roles were 
reversed, and further evaluation is needed to determine 
whether there was interaction between omentin-1 and 
visfatin.
  The present study was a cross-sectional study that 
could only indicate that there was a relationship between 
omentin-1 levels, visfatin levels and CHD. However, the 
study could not demonstrate  the increase of omentin levels 
and decrease of visfatin levels were primary or secondary. 
There were no objective indicators on clinical typing and 
grading of heart function boundaries. All records were based 
on the patient's subjective symptoms. Further research using 
a larger sample size is needed. The study population was 
the elderly; thus, there may be other factors that affected the 
plasma level of omentin -1 and visfatin.
  Adipocytokines, especially the omentin-1 and visfatin, 
have been in the center of research over the recent 
years. Our study found that omentin-1 and visfatin levels 
significantly decreased in CHD patients, and omentin-1 
levels were negatively associated with SBP and visfatin 
levels. Moreover, the plasma levels of omentin-1 and visfatin 
might both be affected by HDL-c levels, and visfatin may be 
an independent risk factor of CHD. These results provide a 
basis for the significance of clinical detection of omentin-1 
and visfatin levels, and a new initiative for the prevention 
and treatment of CHD.
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